ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0378

Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever
Abstract Number: 1109

Comparison of Diagnostic Criteria in Behçet’s Disease and Sensitivity in Diagnosing Severe Manifestations
Abstract Number: 0294

Comparison of Factors Associated with CT-Scan Progression of Interstitial Lung Disease in Rheumatoid Arthritis and Idiopathic Pulmonary Fibrosis. Retrospective Multicenter Study of 144 Patients
Abstract Number: 1533

Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
Abstract Number: 0899

Comparison of Sacroiliac CT Findings in Patients with and Without Ankylosing Spondylitis Aged 50 Years or Older: Preliminary Results of the CASIAGE Study
Abstract Number: 1241

Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
Abstract Number: 0869

Comparison of Two Frailty Definitions in Women with Systemic Lupus Erythematosus
Abstract Number: 1574

Comparison of Urate Quantification in Gout and Asymptomatic Hyperuricemia by Ultrasound and Dual Energy Computed Tomography
Abstract Number: 1370

Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Abstract Number: 1208

Composite Articular Index Including Acute Phase Reactants Should Not Be Used in Patients with Rheumatoid Arthritis Treated with Il6 Inhibitors but May Be Useful in Those Receiving Jak Inhibitors: Ultrasound Evidence
Abstract Number: 1045

Composition of Phospholipid Fatty Acids in Erythrocyte Membranes from Patients with Ankylosing Spondylitis
Abstract Number: 1657

Comprehensive Assessment of Multimorbidity Burden in a Population-based Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 1595

Concern About the COVID-19 Pandemic and Community Mobility Among Systemic Lupus Erythematosus Patients
Abstract Number: 0617

Concerns and Beliefs About COVID-19 Vaccination Among Racial and Ethnic Minority Patients with Rheumatic Disease
Abstract Number: 0671

Concomitant Immunomodulation and Pegloticase Therapy: Experiences with a Variety of Immunomodulatory Agents in Two Community Rheumatology Practices

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].